查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864213

心肺体外迴圈装置市场按产品类型、应用、最终用户和技术划分－2025年至2032年全球预测

Cardiopulmonary Bypass Equipment Market by Product Type, Application, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，心肺体外迴圈设备市场规模将达到 4.561 亿美元，复合年增长率为 4.53%。

关键市场统计数据
基准年 2024 3.1992亿美元
预计年份：2025年 3.3474亿美元
预测年份 2032 4.561亿美元
复合年增长率 (%) 4.53%

对临床实务、采购重点、技术进步以及心肺体外迴圈设备在机构决策架构中的定位进行策略概述

本执行摘要首先将心肺体外迴圈置于心臟外科手术的综合治疗系统中，指出设备的可靠性、生物相容性和手术效率直接影响临床结果。体外循环设备包括用于心血管手术期间体外循环的装置和一次性耗材，并与临床通讯协定、灌注师操作规范和机构采购重点密切相关。随着各医院和专科心臟中心的团队调整工作流程以优化治疗效果并控製成本，了解设备功能、使用者人体工学和病人安全之间的相互作用至关重要。

临床应用受微观层面操作需求（例如易于安装、预充量和与监测系统的兼容性）以及宏观层面因素（例如监管和供应链韧性）的影响。氧合器膜设计和泵浦机制的技术进步降低了併发症率并简化了手术全期管理，但也对培训、耗材库存和供应商提出了新的要求。因此，医院管理者和循环系统支援负责人必须将临床表现数据与采购考量结合，以选择符合本院病例组合和长期资本规划的系统。

本摘要的其余部分以可操作的综合形式呈现，重点介绍结构变化、政策影响、细分细微差别、区域趋势、竞争对手行动以及具体建议，这些内容共同构成了製造商、供应商和投资者即时采取战略行动的基础。

膜设计、泵浦机制、涂层和临床工作流程的进步正在共同重塑采购、临床应用和设备开发路径。

心肺体外迴圈领域正经历变革性的转变，这主要由临床需求、技术创新以及对安全性和效率日益增长的期望共同驱动。膜式氧合器材料的进步，包括改良的中空纤维和平板式设计，在改善气体交换特性的同时，也减少了血液损伤。同时，泵浦技术也朝着更耐用的离心机构和更精确的滚压帮浦控制方向发展，从而改变了灌注师的工作流程和设备配置。

除了设备本身的改进之外，系统性转变也显而易见，重点在于透过涂层和表面处理来降低血栓形成风险。在抗凝血管理复杂的情况下，肝素涂层迴路和其他生物相容性涂层正日益受到重视，这使得涂层系统和非涂层系统之间形成了差异化的价值提案。操作模式（非搏动流与搏动流）的考量也影响医院的采购决策，临床医师需要在血流动力学精确度、设备复杂性和耗材成本之间进行权衡。

在操作方面，积体电路组和一次性平台的使用趋势日益明显，这些设备有望实现更快的换型速度和更低的污染风险，但这些优势必须与废弃物管理和永续性目标相平衡。同时，新生儿和儿科领域的设备应用模式也对低流量和不同预充策略的专用插管和氧合器提出了更高的要求，迫使供应商针对不同的患者群体改进产品。这些变化共同推动了采购决策的更加精细化，将病人安全、临床医生体验和全生命週期成本置于设备选择的核心。

关税引发的供应链变化对零件采购、到岸成本趋势、供应商多元化和采购弹性策略的连锁反应

近期美国政策引发的关税变动为心肺体外迴圈供应链带来了新的挑战，影响了成本结构、库存策略和采购决策。依赖跨境生产的零件製造商，例如氧合器膜所需的特种聚合物、导管和泵壳所需的精密金属零件以及医药级涂层，面临关税风险增加的局面，这将改变其到岸成本。因此，许多供应商正在重新评估其供应链结构，以在维持服务水准的同时保护利润率。

为此，医院和心臟中心的采购团队正在扩展供应商资格框架，并优先考虑多源采购策略，以降低单一供应商风险。在关税导致进口零件相对成本上升的情况下，一些原始设备製造商 (OEM) 正在加快本地化进程，或重新谈判合约以纳入关税转嫁条款。这些措施标誌着采购模式正从纯粹的价格主导转向更具韧性的采购策略，后者更加重视前置作业时间的确定性和零件的可追溯性。

监管和合约方面的影响也十分显着。采购部门和医疗系统越来越要求供应商在更换製造地时，提供关于零件来源和保固范围的透明资讯。如果为了应对关税影响而进行零件替换，导致产品规格发生变化，临床医生和灌注团队可能需要经历一段过渡期。因此，医疗相关人员应制定检验週期、培训更新和库存缓衝计划，以避免在供应商进行製造地长期重组期间手术安排中断。

详细的細項分析揭示了产品系列、临床应用、最终用户环境和技术选择如何相互作用，从而影响采购和采用模式。

详细的细分市场分析为产品开发、临床应用和销售策略提供了切实可行的指导。按产品类型划分，市场格局包括附件、插管、过滤器、氧合器和帮浦。附件包括储液器和导管，而插管则根据解剖结构和血流需求设计用于动脉或静脉。过滤器分为血液浓缩器和白血球去除过滤器，它们在体液管理和发炎调节中发挥不同的作用。氧合器则分为膜式和微孔式两种结构。在膜式氧合器中，平板式和中空纤维式结构在表面积、预充能力和气体交换效率方面各有优劣。泵浦分为离心式和滚压式两种技术，每种技术都会影响溶血风险、维护特性以及与辅助监测系统的兼容性。

应用领域根据使用情境分为成人、新生儿和儿科，会对设备尺寸、预充策略和电路设计产生显着影响。新生儿和儿科应用需要特殊的插管和氧合器功能，以及小批量、高精度的解决方案，而成人应用则更注重耐用性和吞吐量。将最终用户细分为门诊手术中心、心臟外科中心和医院，会影响采购週期和服务预期。门诊中心优先考虑简化的耗材和快速周转率，心臟外科中心通常需要复杂、可自订的系统，而医院则需要在各种病例组合中兼顾多功能性和成本控制。

在技​​术细分中，涂层类型和运作模式是关键决定因素。涂层选项包括肝素涂层和非涂层表面，涂层迴路为高血栓风险患者或寻求减少全身性抗凝血治疗的患者提供了临床依据。运作模式分为非搏动式和搏动式系统，此选择会影响生理支持特性和系统复杂性。总而言之，这些细分视角构成了一个矩阵，製造商和医疗服务提供者可以利用该矩阵来调整产品系列，使其与临床需求、采购限制和使用者偏好观点。

区域监管差异、采购惯例和临床能力如何影响美洲、欧洲、中东和非洲以及亚太地区的商业化和服务策略

区域趋势对美洲、欧洲、中东和非洲以及亚太市场的临床实践、监管路径和商业策略有显着影响。在美洲，大型医院系统和学术机构是主要的机构买家，他们要求产品具备可靠的临床疗效证据、完善的服务网络，并能与电子健康记录 (EHR) 和灌注监测平台无缝整合。该地区的支付模式和医院采购週期鼓励选择性能持久耐用的设备，并建立长期的供应商伙伴关係。

在欧洲、中东和非洲地区（EMEA），监管的多样性和报销政策的差异要求製造商寻求多条核准途径，并收集统一的临床数据以支援价值评估资料。该地区的采购往往侧重于成本效益和全生命週期支持，涵盖从先进的心臟中心到资源匮乏的医疗机构等各种医疗服务环境。亚太地区的特点是心臟外科手术能力的快速扩张、对本地製造的投资以及对床边诊疗优化的日益重视。亚太地区的需求成长主要受手术量增加以及对医疗设备可负担性和本地服务能力的期望不断提高的驱动。

临床通讯协定、人员训练架构和废弃物管理法规的区域差异会对设备设计和售后服务产生实际影响。製造商应根据区域报销差异、当地临床证据的产生以及快速技术支援的后勤需求，调整打入市场策略。与区域分销商建立策略合作伙伴关係，并投资于灌注团队和手术人员的培训，对于推动这些多元化市场中的产品普及至关重要。

现有製造商、专业创新者和以服务为导向的供应商之间的竞争和策略应对，决定了市场领导地位和商业性差异化。

心肺体外迴圈领域的竞争动态由三者构成：既有成熟的外科设备製造商，也有专业的体外循环系统供应商，还有专注于利基创新技术的新兴企业。现有企业凭藉涵盖耗材、设备和综合服务合约的广泛产品系列，形成了高昂的转换成本和较长的产品生命週期。同时，规模较小的公司和新兴企业则透过新型薄膜材料、低预充量氧合器设计以及专科中心和研究型医院的先进泵浦控制演算法来实现差异化竞争。

市场参与企业正积极与临床中心合作，共同开发下一代系统，检验新型涂层，并进行上市后研究，以证明其在实际应用中的益处。为因应采购压力和关税风险，供应链协作、契约製造模式和选择性垂直整合是常见的策略。此外，他们还在投资数位化能力，例如设备遥测和预测性维护，以提高运转率，并证明其价值远超过初始购买成本。

销售和商务团队面临的挑战在于，如何清楚地向循环系统、心臟外科医师和采购委员会阐明产品的临床价值。这需要提供证据，证明产品在相关生命週期内能够降低併发症发生率、简化工作流程并降低总营运成本，而不仅依赖价格作为差异化因素。能够将可靠的临床支援、快速回应的技术服务和灵活的合约选项相结合的公司，将更容易获得医院系统和专科心臟中心的青睐。

製造商和供应商可采取的切实可行的策略重点，以优化其产品组合、保障供应链安全、产生临床证据、拓展服务范围并实现永续性目标。

产业领导者可以采取切实可行的优先事项，在应对营运瓶颈的同时，巩固市场地位并提升临床疗效。首先，应优先优化产品组合，使产品复杂性与核心终端使用者需求相符；在临床证据不支持差异化的情况下，减少SKU数量；并将创新重点放在新生儿、儿科和成人等细分市场需要独特解决方案的领域。其次，应投资于供应链韧性，实现关键零件供应商多元化，并协商合约保护条款，以降低关税和物流波动带来的风险。

第三，我们将深化临床伙伴关係，以支持实证医学证据的生成，包括建立註册登记系统和进行合作研究，检验膜类型、涂层和脉动模式在相关患者群体中的益处。第四，我们将拓展售后服务模式，纳入远距离诊断、预测性维护和培训项目，从而减少停机时间，并提高灌注医护人员的信心。第五，我们将根据不同地区优化市场推广策略，重点关注欧洲市场的监管合规性和价值提案材料，美洲市场的性能和服务，以及亚太地区的可负担性和本地化支持。

最后，将永续性和减少废弃物融入产品和包装设计中，以满足医疗机构的 ESG 目标和不断发展的采购标准——共同实施这些措施可以帮助製造商和供应商在不断变化的政策和供应链环境中实现可衡量的临床效益、增强商业性差异化并降低营运风险。

研究的基础研究采用严谨的混合方法，结合临床医生访谈、监管审查和技术文献，以检验营运见解并得出策略重点。

本分析的研究结合了对临床医生、循环系统、采购人员和行业高管的定性访谈，以及透过监管文件、技术白皮书和同行评审的临床文献进行的二次检验。主要研究着重于了解代表性医院、心臟中心和门诊手术中心的实际设备表现、临床医生偏好、服务期望和采购限制。受访者特意包括服务成人和儿童患者的循环系统，以了解设备在各种临床应用频谱下的表现。

二手资料提供了薄膜材料、泵浦机构和涂层技术的技术背景，并用于检验调查方法中出现的主题。采用横断面主题分析法，辨识出反覆出现的营运挑战、技术重点与采购行为。然后，将这些主题与产品细分和区域特征相匹配，从而得出切实可行的建议。透过反覆的专家检验以及对影响设备设计和标籤的最新法规资讯的审查，确保了建议的准确性和相关性。

这种综合方法促成了切实可行的综合分析，指导了商业策略、临床应用路径和采购决策，而无需依赖推测性的市场预测。最终形成了一个坚实的证据基础，使相关人员能够确定投资优先事项、调整市场推广策略，并使产品蓝图与临床和营运实际情况相符。

本文综合阐述了各项策略要务，阐明了技术创新、供应链韧性和精准商业性策略如何协同作用，以支持临床应用和营运稳定性。

总之，心肺体外迴圈领域正处于一个转折点，技术创新、政策压力和不断变化的临床需求相互交织，重塑采购和临床实践。氧合器设计、帮浦机制和表面涂层技术的进步带来了切实的临床益处，但其成功应用取决于与服务安排、临床医生培训和筹资策略的精心协调。关税导致的供应链调整凸显了采购管道多元化和提高组件采购路径透明度的必要性，而不同地区法规和临床能力的差异则要求根据特定市场采取量身定制的方法。

专注于建立稳健供应链、聚焦产品系列、建立强大的临床伙伴关係关係以及提供全面售后服务支援的製造商，将更有能力满足包括医院、心臟中心和门诊机构在内的医疗机构的复杂需求。同样，将设备选择与员工培训、库存管理和永续性考量相结合的医疗服务提供者，将能够最大限度地提高临床疗效和营运效率。本摘要中概述的策略行动，为希望在不久的将来平衡创新应用与切实可行的营运风险管理的相关人员提供了蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在小儿心臟手术中越来越多地采用小型化体外循环系统（以减少预充量和发炎反应）
  • 将即时血流动力学监测感测器整合到心肺体外迴圈迴路中，以提高患者安全性和治疗效果
  • 开发生物相容性氧合器膜涂层，以减少体外循环手术期间的血液损伤和术后併发症
  • 携带式体外生命支持在加护治疗环境中紧急转运场景中的出现
  • 从滚压泵技术过渡到磁浮离心式帮浦，以优化血流稳定性并最大限度地减少手术期间的溶血。
  • 扩大一次性帮浦和氧合器模组的规模，以简化灭菌工作流程并防止污染风险。
  • 在体外循环手术中引入人工智慧演算法，用于预测灌注参数管理和自动系统警报

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章心肺体外迴圈装置市场（依产品类型划分）

  • 配件
    • 水库
    • 管子
  • 套管
    • 动脉
    • 静脉注射用
  • 筛选
    • 血液浓缩器
    • 白血球去除装置
  • 人工肺
    • 膜类型
      • 平板型
      • 中空纤维
    • 微孔
  • 泵浦
    • 离心式
    • 滚筒

第九章 依应用分類的心肺体外迴圈装置市场

  • 成人版
  • 新生
  • 孩子们

第十章 以最终用户分類的心肺体外迴圈装置市场

  • 门诊手术中心
  • 心臟外科中心
  • 医院

第十一章 依技术分類的心肺体外迴圈装置市场

  • 涂层类型
    • 肝素涂层
    • 未涂层
  • 按操作模式
    • 非脉动
    • 脉动

第十二章心肺体外迴圈装置市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章心肺体外迴圈装置市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国心肺体外迴圈装置市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Terumo Corporation
    • LivaNova PLC
    • Medtronic plc
    • Getinge AB
    • Nipro Corporation
    • JMS Co., Ltd
    • XENIOS AG
    • Fresenius Medical Care AG & Co. KGaA
    • Baxter International Inc.
    • Haemonetics Corporation
Product Code: MRR-757B1C9CB0B8

The Cardiopulmonary Bypass Equipment Market is projected to grow by USD 456.10 million at a CAGR of 4.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 319.92 million
Estimated Year [2025] USD 334.74 million
Forecast Year [2032] USD 456.10 million
CAGR (%) 4.53%

A strategic overview placing cardiopulmonary bypass equipment within clinical practice, procurement priorities, technological progress and institutional decision frameworks

This executive summary opens by situating cardiopulmonary bypass equipment within the broader continuum of cardiac surgical care, where device reliability, biocompatibility, and procedural efficiency directly influence clinical outcomes. The equipment set covered spans devices and disposables that enable extracorporeal circulation during cardiac procedures, and it interacts closely with clinical protocols, perfusionist practice, and institutional procurement priorities. As teams across hospitals and specialized cardiac centers recalibrate workflows to optimize outcomes and contain costs, understanding the interplay among device functionality, user ergonomics, and patient safety has become essential.

Clinical adoption is shaped by both micro-level operational needs-such as ease of setup, priming volumes, and compatibility with monitoring systems-and macro-level forces including regulatory scrutiny and supply chain resilience. Technological advances in oxygenator membrane design and pump mechanics have reduced complication rates and simplified perioperative management, yet they have also introduced new decision criteria around training, disposables inventory, and vendor consolidation. Consequently, hospital administrators and perfusion leaders must synthesize clinical performance data with procurement considerations to select systems that align with institutional case mix and long-term capital plans.

The introduction concludes by framing the remainder of this summary as a practical synthesis: it highlights structural shifts, policy influences, segmentation nuances, regional dynamics, competitor behaviors, and targeted recommendations that together form a foundation for immediate strategic action by manufacturers, providers, and investors.

How advancements in membrane design, pump mechanics, coatings, and clinical workflows are collectively reshaping procurement, clinical practice, and device development pathways

The landscape for cardiopulmonary bypass equipment is undergoing transformative shifts driven by converging clinical priorities, engineering innovation, and heightened expectations for safety and efficiency. Advances in membrane oxygenator materials, including the refinement of hollow fiber geometries and flat plate designs, are delivering improved gas exchange characteristics while reducing blood trauma. At the same time, pump technologies have evolved with more durable centrifugal mechanics and more precise roller pump controls, altering perfusionist workflows and inventory configurations.

Beyond device evolution, systemic change is evident in the emphasis on coatings and surface treatments to mitigate thrombogenicity. Heparin-coated circuits and alternative biocompatible coatings are increasingly considered where anticoagulation management is complex, creating a differentiated value proposition between coated and non-coated systems. Mode of operation considerations-non-pulsatile versus pulsatile flow-are also influencing hospital purchasing decisions as clinicians weigh hemodynamic fidelity against device complexity and cost of disposables.

Operationally, there is a clear shift toward integrated circuit sets and single-use platforms that promise faster turnover and reduced contamination risk, but these benefits must be balanced against waste management and sustainability goals. In parallel, adoption patterns in neonatal and pediatric subsegments demand specialized cannulae and oxygenators sized for lower flow volumes and different priming strategies, prompting suppliers to refine product families to match patient demographics. Taken together, these shifts are driving a more nuanced procurement dialogue that places patient safety, clinician experience, and lifecycle total cost at the center of equipment selection.

The ripple effects of tariff-induced supply chain shifts on component sourcing, landed cost dynamics, supplier diversification, and procurement resilience strategies

Recent tariff developments originating from United States policy actions have introduced novel considerations across supply chains for cardiopulmonary bypass equipment, affecting cost structures, inventory strategies, and sourcing decisions. Manufacturers that rely on cross-border production of components such as specialized polymers for oxygenator membranes, precision metalwork for cannulae and pump housings, or pharmaceutical-grade coatings face increased exposure to duties that can alter landed costs. As a result, many suppliers are reassessing their supply chain architectures to preserve margin while maintaining service levels.

Procurement teams at hospitals and cardiac centers are responding by expanding supplier qualification frameworks and prioritizing dual-source strategies that reduce single-vendor risk. Where tariffs increase the relative cost of imported components, some original equipment manufacturers are accelerating localization efforts or renegotiating contracts to include tariff pass-through clauses. These measures underscore a shift from purely price-driven sourcing to a more resilient procurement posture that values lead-time assurance and component traceability.

Regulatory and contracting effects are also apparent: purchasing groups and health systems increasingly require transparency on the origin of components and warranty implications when manufacturing locations change. Clinicians and perfusion teams may face transition periods when product specifications shift due to component substitutions intended to mitigate tariff impacts. Therefore, institutional stakeholders should plan for validation cycles, training refreshers, and inventory buffers to avoid disruptions to surgical schedules while suppliers pursue longer-term realignment of manufacturing footprints.

Deep segmentation analysis revealing how product families, clinical applications, end-user environments, and technology choices interact to shape procurement and adoption patterns

Analyzing the market through detailed segmentation reveals actionable implications for product development, clinical adoption, and sales strategies. When viewed by product type, the landscape encompasses Accessories, Cannulae, Filters, Oxygenators, and Pumps; Accessories include Reservoirs and Tubing, and Cannulae comprise Arterial and Venous variants designed for distinct anatomical and flow requirements. Filters span Hemoconcentrators and Leukocyte Filters, which play differentiated roles in fluid management and inflammatory modulation, while Oxygenators are available in Membrane and Microporous constructs. Within membrane oxygenators, Flat Plate and Hollow Fiber architectures present tradeoffs in surface area, priming volume, and gas transfer efficiency. Pumps bifurcate into Centrifugal and Roller technologies, each with implications for hemolysis risk, maintenance profiles, and compatibility with ancillary monitoring systems.

Application segmentation differentiates adult, neonatal, and pediatric use cases, a distinction that materially affects device sizing, priming strategies, and circuit design. Neonatal and pediatric applications demand low-volume, high-precision solutions with specialized cannulae and oxygenator characteristics, whereas adult applications often emphasize durability and throughput. End user segmentation across Ambulatory Surgery Centers, Cardiac Surgery Centers, and Hospitals influences purchasing cycles and service expectations; ambulatory centers prioritize streamlined disposables and rapid turnover, cardiac surgery centers often demand high-performance customizable systems, and hospitals balance versatility with cost containment across broader case mixes.

Technology segmentation highlights coating type and mode of operation as pivotal decision variables. Coating options include Heparin Coated and Non Coated surfaces, with coated circuits offering a clinical rationale in patients at higher thrombotic risk or where lower systemic anticoagulation is desirable. Mode of operation divides into Non Pulsatile and Pulsatile systems, a choice that informs both physiological support characteristics and system complexity. Collectively, these segmentation lenses create a matrix that manufacturers and providers can use to align product portfolios with clinical needs, procurement constraints, and user preferences.

How regional regulatory diversity, procurement practices and clinical capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and service strategies

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, institutional purchasing is characterized by large hospital systems and academic centers that demand robust evidence of clinical efficacy, strong service networks, and integration with electronic health records and perfusion monitoring platforms. Payment models and hospital procurement cycles in this region incentivize durable equipment performance and long-term vendor partnerships.

In Europe, Middle East & Africa, regulatory diversity and reimbursement variability require manufacturers to pursue harmonized clinical data that can support multiple approval pathways and value dossiers. Procurement in this region often emphasizes cost-effectiveness and lifecycle support across disparate healthcare delivery settings, from advanced cardiac centers to under-resourced facilities. The Asia-Pacific region is marked by rapid expansion of cardiac surgical capacity, investment in local manufacturing, and a growing emphasis on point-of-care optimization. Demand in Asia-Pacific is driven by both rising procedure volumes and evolving expectations for device affordability and local service capabilities.

Across regions, differences in clinical protocols, staff training paradigms, and waste management regulations create practical implications for device design and aftersales service. Manufacturers should calibrate market entry strategies to address regional reimbursement nuances, local clinical evidence generation, and the logistical requirements of providing responsive technical support. Strategic partnerships with regional distributors and investments in education for perfusion teams and surgical staff will be critical to unlock adoption across these heterogeneous markets.

Competitive behaviors and strategic responses among established manufacturers, focused innovators, and service-oriented providers that define market leadership and commercial differentiation

Competitive dynamics in the cardiopulmonary bypass equipment space are defined by a mix of established surgical device manufacturers, specialized perfusion system providers, and emerging technology entrants focused on niche innovations. Incumbent manufacturers leverage broad portfolios that span disposables, capital equipment, and integrated service contracts, creating high switching costs and extended product lifecycles. Meanwhile, smaller firms and start-ups push differentiation through novel membrane materials, low-priming-volume oxygenator designs, and advanced pump control algorithms that appeal to specialty centers and research hospitals.

Market participants are increasingly pursuing partnerships with clinical centers to co-develop next-generation systems, validate novel coatings, and run post-market surveillance studies that demonstrate real-world benefits. Supply chain collaborations, contract manufacturing models, and selective vertical integration are common strategic responses to procurement pressures and tariff exposure. Additionally, companies are investing in digital capabilities around device telemetry and predictive maintenance to enhance uptime and demonstrate value beyond the initial purchase.

For sales and commercial teams, the imperative is to articulate clinical value clearly to perfusionists, cardiac surgeons, and purchasing committees. This includes providing evidence of reduced complication rates, simplified workflows, and total cost of operation over relevant lifecycle horizons without relying solely on price as the differentiator. Firms that can combine robust clinical support, rapid technical service, and flexible contracting options will gain traction among hospital systems and specialized cardiac centers.

Practical strategic priorities for manufacturers and providers to optimize portfolios, secure supply chains, generate clinical evidence, expand service offerings, and address sustainability objectives

Industry leaders can pursue a set of actionable priorities to strengthen market positions and support clinical outcomes while addressing operational constraints. First, prioritize portfolio rationalization that aligns product complexity with core end-user needs, reducing SKUs where clinical evidence does not support differentiation and concentrating innovation where neonatal, pediatric, or adult subsegments demand unique solutions. Second, invest in supply chain resilience by diversifying suppliers of critical components and negotiating contractual protections that mitigate tariff and logistics volatility.

Third, deepen clinical partnerships that support evidence generation, including registries and collaborative studies that validate the benefits of membrane types, coatings, and pulsatile modality in relevant patient cohorts. Fourth, expand aftersales service models to include remote diagnostics, predictive maintenance, and training programs that reduce downtime and improve adoption confidence among perfusion staff. Fifth, tailor go-to-market approaches by region: emphasize regulatory alignment and value dossiers in Europe, performance and service in the Americas, and affordability plus local support in Asia-Pacific.

Finally, integrate sustainability and waste reduction into product and packaging design to meet institutional ESG goals and evolving procurement criteria. Executed together, these actions will help manufacturers and providers deliver measurable clinical benefits, strengthen commercial differentiation, and reduce operational risk in a shifting policy and supply chain environment.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and technical literature to validate operational insights andinform strategic priorities

The research underlying this analysis synthesizes primary qualitative interviews with clinicians, perfusionists, procurement leaders, and industry executives alongside secondary validation from regulatory filings, technical white papers, and peer-reviewed clinical literature. Primary engagement focused on understanding real-world device performance, clinician preferences, service expectations, and procurement constraints across a representative set of hospitals, cardiac centers, and ambulatory surgical facilities. Interview sampling deliberately included perfusionists working with both adult and pediatric populations to capture device performance across the clinical spectrum.

Secondary sources provided technical context on membrane materials, pump mechanics, and coating science and were used to corroborate themes that emerged in interviews. The methodology applied a cross-sectional thematic analysis to identify recurring operational pain points, technology priorities, and procurement behaviors, and these themes were mapped against product segmentation and regional dynamics to derive actionable recommendations. To ensure accuracy and relevance, the analysis included iterative validation with subject matter experts and a review of recent regulatory communications that affect device design and labeling.

This combined approach produced a pragmatic synthesis designed to inform commercial strategy, clinical adoption pathways, and procurement decisions without relying on speculative market projections. The result is a robust evidence base that stakeholders can use to prioritize investments, modify go-to-market strategies, and align product roadmaps with clinical and operational realities.

Synthesis of strategic imperatives showing how technology, supply chain resilience and targeted commercial approaches converge to support clinical adoption and operational stability

In conclusion, the cardiopulmonary bypass equipment environment is at an inflection point where technology improvements, policy pressures, and evolving clinical expectations converge to reshape procurement and clinical practice. Advances in oxygenator design, pump mechanics, and surface coatings are delivering tangible clinical benefits, yet their successful adoption depends on careful alignment with service capabilities, clinician training, and procurement strategies. Tariff-induced supply chain adjustments have underscored the need for diversified sourcing and greater transparency around component provenance, while regional differences in regulation and clinical capacity call for tailored market approaches.

Manufacturers that emphasize resilient supply chains, focused product portfolios, robust clinical partnerships, and comprehensive aftersales support will be better positioned to meet the complex needs of hospitals, cardiac centers, and ambulatory facilities. Similarly, providers that integrate device selection with staff training, inventory management, and sustainability considerations will maximize clinical outcomes and operational efficiencies. The strategic actions outlined in this summary offer a roadmap for stakeholders seeking to balance innovation adoption with pragmatic operational risk management in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of miniaturized extracorporeal circulation systems in pediatric cardiac surgery to reduce priming volumes and inflammatory response
  • 5.2. Integration of real-time hemodynamic monitoring sensors into cardiopulmonary bypass circuits for enhanced patient safety and outcomes
  • 5.3. Development of biocompatible oxygenator membrane coatings to mitigate blood trauma and reduce postoperative complications in bypass procedures
  • 5.4. Emergence of portable extracorporeal life support devices for emergency transport scenarios in critical care settings
  • 5.5. Transition from roller pump technology to magnetic levitation centrifugal pumps to optimize flow stability and minimize hemolysis during surgeries
  • 5.6. Expansion of single-use disposable pump and oxygenator modules to streamline sterilization workflows and prevent contamination risks
  • 5.7. Implementation of artificial intelligence algorithms for predictive perfusion parameter management and automated system alerts during bypass

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiopulmonary Bypass Equipment Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Reservoirs
    • 8.1.2. Tubing
  • 8.2. Cannulae
    • 8.2.1. Arterial
    • 8.2.2. Venous
  • 8.3. Filters
    • 8.3.1. Hemoconcentrators
    • 8.3.2. Leukocyte Filters
  • 8.4. Oxygenators
    • 8.4.1. Membrane
      • 8.4.1.1. Flat Plate
      • 8.4.1.2. Hollow Fiber
    • 8.4.2. Microporous
  • 8.5. Pumps
    • 8.5.1. Centrifugal
    • 8.5.2. Roller

9. Cardiopulmonary Bypass Equipment Market, by Application

  • 9.1. Adult
  • 9.2. Neonatal
  • 9.3. Pediatric

10. Cardiopulmonary Bypass Equipment Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Cardiac Surgery Centers
  • 10.3. Hospitals

11. Cardiopulmonary Bypass Equipment Market, by Technology

  • 11.1. Coating Type
    • 11.1.1. Heparin Coated
    • 11.1.2. Non Coated
  • 11.2. Mode Of Operation
    • 11.2.1. Non Pulsatile
    • 11.2.2. Pulsatile

12. Cardiopulmonary Bypass Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiopulmonary Bypass Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiopulmonary Bypass Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Terumo Corporation
    • 15.3.2. LivaNova PLC
    • 15.3.3. Medtronic plc
    • 15.3.4. Getinge AB
    • 15.3.5. Nipro Corporation
    • 15.3.6. JMS Co., Ltd
    • 15.3.7. XENIOS AG
    • 15.3.8. Fresenius Medical Care AG & Co. KGaA
    • 15.3.9. Baxter International Inc.
    • 15.3.10. Haemonetics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIOPULMONARY BYPASS EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIOPULMONARY BYPASS EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIOPULMONARY BYPASS EQUIPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET